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Abstract
Most subunit vaccines require adjuvants in order to induce protective immune responses to the targeted pathogen.
However, many of the potent immunogenic adjuvants display unacceptable local or systemic reactogenicity. Liposomes are
spherical vesicles consisting of single (unilamellar) or multiple (multilamellar) phospholipid bi-layers. The lipid membranes
are interleaved with an aqueous buffer, which can be utilised to deliver hydrophilic vaccine components, such as protein
antigens or ligands for immune receptors. Liposomes, in particular cationic DDA:TDB vesicles, have been shown in animal
models to induce strong humoral responses to the associated antigen without increased reactogenicity, and are currently
being tested in Phase I human clinical trials. We explored several modifications of DDA:TDB liposomes - including size,
antigen association and addition of TLR agonists – to assess their immunogenic capacity as vaccine adjuvants, using
Ovalbumin (OVA) protein as a model protein vaccine. Following triple homologous immunisation, small unilamellar vesicles
(SUVs) with no TLR agonists showed a significantly higher capacity for inducing spleen CD8 IFNc responses against OVA in
comparison with the larger multilamellar vesicles (MLVs). Antigen-specific antibody reponses were also higher with SUVs.
Addition of the TLR3 and TLR9 agonists significantly increased the adjuvanting capacity of MLVs and OVA-encapsulating
dehydration-rehydration vesicles (DRVs), but not of SUVs. Our findings lend further support to the use of liposomes as
protein vaccine adjuvants. Importantly, the ability of DDA:TDB SUVs to induce potent CD8 T cell responses without the need
for adding immunostimulators would avoid the potential safety risks associated with the clinical use of TLR agonists in
vaccines adjuvanted with liposomes.
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Introduction
Majority of vaccines currently in development belong to the
category of subunit vaccines, consisting of recombinant or purified
pathogen-specific proteins, or encoded (DNA) antigens that will be
expressed and presented in vivo. Administered alone subunit
vaccines have low efficacy in activating the immune system and
require the addition of adjuvants in order to induce a measurable
immune response to the antigen (Ag), through the activation of the
innate, and subsequently the adaptive, immune system. Ideally,
the adjuvant should be able to improve Ag uptake by antigen
presenting cells (APCs) and induce an Ag-specific immune
response while eliciting minimal toxicity. Liposomes are a type
of adjuvant that can potentially satisfy all these criteria.
Liposomes are lipid-bilayer vesicular structures within which
various substances can be entrapped, and delivered in vivo in a
discrete and safe manner, protected from degradation. Adminis-
tration of therapeutic agents inside liposomes has been employed
over several decades in enzyme replacement therapy [1,2],
intracellular delivery of chelating agents in cases of heavy metal
poisoning [3] and treatment of cancer [4]. More recently,
liposomes have found application as vaccine adjuvants [5,6,7]:
the ability to prevent Ag degradation and clearance, coupled with
enhancing its uptake by professional APCs, have marked
liposomes as useful vehicles for the delivery of a diverse array of
vaccine antigens [8,9,10].
The choice of the lipid used in the synthesis of liposomes affects
their physico-chemical and immunogenic properties, and exten-
sive research using many diverse lipids, in particular phospholip-
ids, has been carried out with the aim of increasing and optimising
the adjuvanting effect of liposome-delivered antigens (reviewed in
[11,12]). Phospholipid molecules contain a non-polar region
(composed of one or more fatty acid chains, or cholesterol) and
a polar region consisting of a phosphate group linked to tertiary or
quarternary ammonium salts. The polar region can have a net
negative (anionic), neutral or positive (cationic) surface charge,
which is one of the main determinants of liposome behaviour and
function. More specifically, liposomes incorporating the synthetic
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amphiphilic cationic lipid compound dimethyldioctadecylammo-
nium (DDA) combined with an immunostimulatory component,
trehalose 6,6-dibehenate (TDB), a non- toxic analogue of the
mycobacterial cell wall component trehalose 6,69 dimycolate
(TDM), have been shown to strongly enhance cellular and
humoral responses against a protein antigen [13]. Adjuvanticity
of the cationic DDA:TDB liposomes and sustained protection
against disease challenge has been demonstrated in particular with
a tuberculosis vaccine candidate [14,15] and has good potential
for application in a range of other diseases [16].
The antigen to be delivered can be either entrapped within the
aqueous compartment of the liposomes, incorporated into the lipid
bilayer membrane (hydrophobic antigens) or adsorbed to the
liposomal surface through covalent or charge-dependent, electro-
static, interaction [17,18,19] and past studies have addressed the
relative merits of the Ag/liposomal vesicle configuration in
enhancing the adjuvant effect of liposomes [20]. More recently,
with the advanced recognition of the roles of innate pathogen
receptors in adaptive immunity, researchers have been exploring
the potential for enhancing immunogenicity of cationic liposomes
through addition of Toll-Like Receptor (TLR) agonists [21,22,23].
In turn, liposome encapsulation of CpG oligonucleotides has been
shown to enhance and prolong innate system stimulation and
significantly improved the CpG-induced immune protection
against Listeria [24,25].
TLRs signal through two main intracellular pathways: MyD88-
dependent (TLRs 2, 4, 5 and 9) and MyD88–independent (TLRs
3 and 4) [26]. Signalling through both pathways simultaneously
was shown to have a synergistic effect on their ability to induce
pro-inflammatory cytokine production in mice [27], whereas
multiple agonists of the same pathway can be mutually
antagonistic [28]. Unlike the cell surface-bound members of the
TLR family, several of these receptors (TLRs 3, 7, 8 and 9) reside
within the endosomal cellular compartment [29,30] and thus
encounter internalised antigens. It has been shown that endoso-
mally located TLRs can enhance Ag presentation by DCs through
the MHC class I pathway (cross-presentation), resulting in
increased murine CD8 T cell responses [31,32].
Here we describe a study conducted to further examine the
adjuvant properties of cationic liposome/TLR agonist complexes in
inducing humoral and cellular responses to a protein Ag, and to
extend previous observations by investigating the effect of liposome
size and lamellarity. We focused on DDA:TDB cationic liposomes
combined with TLR3 and TLR9 agonists (poly I:C and CpG ODN
M362, respectively) and used whole Ovalbumin protein (OVA) as a
model protein vaccine. As mentioned above, TLRs 3 and 9 are both
endosomally located, although they differ in their requirement for
MyD88 in the downstream signalling [28]. Poly I:C and CpG ODN
were delivered either entrapped inside the liposomes or adsorbed to
the liposomal surface, in order to assess whether encapsulating these
TLR agonists within liposomes is more likely to activate their
endosomally located receptors and, in particular, enhance CD8 T
cell responses to OVA protein.
Results
Liposome formulations
We investigated three types of DDA:TDB liposomes of different
size and lamellarity. Multilamellar vesicles (MLVs) are around
500 nm in diameter and consist of several concentric lipid bi-layers.
Dehydration-rehydration vesicles (DRVs) are lipid bi-layer mem-
brane vesicles which encapsulate the antigen and/or TLR agonist.
Small unilamellar vesicles (SUVs) are single membrane vesicles,
around 60 to 120 nm in diameter. The diameter of both MLVs and
SUVs increased with the addition of protein Ag. Liposomes were
formulated with whole OVA protein either attached to the liposomal
surface through electrostatic forces (MLV, DRV and SUV
formulations) or entrapped within the liposomes (DRV formulations).
Some of the DDA:TDB/OVA formulations were further combined
with TLR agonists poly I:C (pIC) and/or CpG, which were again
either surface-adsorbed or entrapped. Analysis of the proportion of
the OVA protein retained within the different liposomal formulations
over time demonstrated good stability in Tris buffer. Under
simulated in vivo conditions (Tris buffer supplemented with 50%
FCS and incubated at 37uC), although there was an increased release
of OVA, over 50% of the antigen was still associated with the
liposomes after 96 h of incubation (Figure S1).
Liposome characterisation
Physico-chemical characterisation of all liposomal formulations
was carried out by measuring the size, polydispersity, Zeta (Z)-
potential and the proportion of OVA protein incorporated in the
formulations (Table 1 and Figure 1). Addition or incorporation of
the negatively charged OVA protein and nucleic acid-based pIC
and CpG into the cationic liposomes was found to affect the
particle size and zeta potential. Empty DDA:TDB MLV liposomes
to which soluble OVA was added were 667.2672.6 nm in
diameter, with a positive charge (Z-potential = 46.2663.7 mV).
Adsorption of OVA resulted in a size increase to
1047.16135.8 nm, due to aggregation of vesicles promoted by
antigen interactions, with a negligible rise in Z-potential. Further
addition of CpG to the liposome surface resulted in a non-
significant size increase and a drop in Z-potential to 13.265.3.
Liposomes encapsulating OVA, DRV(OVA), were significantly
smaller than the vesicles prepared with surface-complexed OVA
(546623.7 vs 1047.16135.8 nm). Entrapment of CpG alone
increased the liposome size to 1234626.7 nm and reduced the Z-
potential to below neutral (23.765.6 mV), suggesting a reconfig-
uration of the system in comparison to DRV(OVA). Entrapment
of pIC in combination with CpG resulted in vesicles of a similar
size (1336.2635.8 nm) with a negative zeta potential (240.26
6.7 mV), indicating that some of the material may also be
electrostatically adsorbed to the surface of the DRV as well as
entrapped, thereby masking the cationic nature of the liposome
surface. Entrapment of all three components OVA, CpG and pIC
resulted in no significant change in zeta potential and led to a
further increase in size to 1399.26172.5 nm.
Empty DDA:TDB SUV liposomes have an average size of
67.8612.8 nm. Surface-adsorption of OVA increased their size to
591.9625.7 nm, and adding CpG alone or with pIC resulted in
even larger liposomes (785.86123.1 nm and 985.86200 nm,
respectively). The addition of the TLR agonists also inverted the
Z-potential from 33.9867.2 mV to 243.9963.7 mV and
250.12611 mV, respectively.
SUVs induce strong CD8 T cell and antibody responses to
OVA
We first investigated the adjuvant potential of DDA:TDB
liposomes formulated with OVA protein alone, with no added
TLR agonists (Figure 2). One mouse-dose of each liposome
formulation contained 250 mg DDA and 50 mg TDB; one dose of
OVA was 20 mg. We tested SUVs and MLVs with surface-adsorbed
OVA protein as well as DRVs with OVA entrapped within the
liposomes, in a regime consisting of three homologous injections of
each formulation intramuscularly, two weeks apart. Animals were
followed-up for 10 weeks post last injection and total IgG responses
in the serum measured two weeks after every vaccination and at two
further time-points (10 and 14 weeks from first immunisation). At
Cationic Liposomes as Vaccine Adjuvants
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the final time-point (14 weeks) the animals were sacrificed and
spleen CD4 and CD8 T cell IFNc responses assessed.
Adsorbing OVA to SUVs (SUV(OVA)) strongly enhanced the
spleen CD8 IFNc responses (p,0.01) (Figure 2A). MLVs with
surface-adsorbed OVA (MLV(OVA)) and DRVs encapsulating
the protein (DRV(OVA)) did not significantly increase CD8
(Figure 2A) nor CD4 (Figure 2B, 2C) responses as compared to
MLVs combined with OVA in solution (MLV+sOVA). A triple
immunisation with OVA protein alone did not induce any CD4 or
CD8 responses. The CD4 IFNc responses in the spleen were also
significantly higher following vaccination with SUV(OVA) in
comparison to MLV+sOVA (p,0.05). Median responses after
DRV(OVA) vaccination were higher for both CD8 and CD4
splenocytes as compared with MLV(OVA) liposomes, but did not
reach statistical significance (Figure 2A, 2B and 2C).
Total IgG titres against whole OVA protein were lowest in the
animals vaccinated with MLV+sOVA and similar to MLVs with
surface adsorbed OVA. At the peak timepoint (2 weeks post last
injection) end-point titres in the DRV(OVA) and SUV(OVA) groups
were up to 100-fold higher than those receiving the MLV
formulations. The significantly higher titres in these two groups
persisted until the final timepoint (p,0.01 for SUV(OVA) and
p,0.05 for DRV(OVA) when compared to MLV+sOVA, Figure 2D).
Addition of TLR3 and TLR9 agonists significantly
increases CD8 T cell immunogenicity of MLV(OVA) and
DRV(OVA), but not SUV(OVA)
We then tested the immunostimulatory effect of adding pIC and
CpG ODN to the liposome/OVA formulations, in an identical
vaccination regimen of three homologous injections two weeks
Figure 1. Size distribution (bars) and Z-potential (points) of DDA:TDB liposomal formulations with OVA±pIC/CpG.
doi:10.1371/journal.pone.0034255.g001
Table 1. Liposome specifications of the DDA:TDB formulations containing OVA and TLR agonists.
Formulation Size (nm) ± SD Z-potential (mV) ± SD Polydispersity Index (PDI)
Proportion OVA incorporated
(% of total dose)
MLV+sOVA 667.2672.6 46.2663.7 0.32160.02 86%
MLV(OVA) 10476135.8 48.7612.1 0.36760.01 95%
MLV(OVA,CpG) 1378.66176 13.265.3 0.46360.02 44%
DRV(OVA) 546623.7 45.468.6 0.35360.01 93%
DRV(CpG)+sOVA 1234626.7 23.765.6 0.33660.01 74%
DRV(pIC,CpG)+sOVA 1336.2635.8 240.266.7 0.41060.01 80%
DRV(pIC,CpG)+MLV(OVA) 1116.96176 22.26612.37 0.35960.08 87%
DRV(OVA,pIC,CpG) 1399.26172.5 244.9611.1 0.35560.01 85%
SUV(OVA) 591.9625.7 33.9867.2 0.41560.03 85%
SUV(OVA,CpG) 785.86123.1 243.9963.7 0.40360.01 56%
SUV(OVA,pIC,CpG) 985.86200 250.12611 0.44260.01 60%
doi:10.1371/journal.pone.0034255.t001
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apart (Figure 3). The doses of TLR agonists administered per
immunisation were 20 mg CpG and 50 mg pIC.
Adding CpG to MLV(OVA) increased the CD8+IFNc+
responses (Mann-Whitney unpaired t-test, p = 0.002) to levels
comparable to those observed after vaccination with OVA, pIC
and CpG in solution (sOVA+pIC+GpC), despite the reduced
proportion of the incorporated OVA antigen (44%, Table 1).
Entrapping poly I:C and CpG within DDA:TDB liposomes
(DRV(OVA, pIC, CpG)) also resulted in significantly enhanced
CD8 responses (Welch’s unpaired t-test for unequal variances,
p = 0.0028) compared to DRV(OVA), although marginally lower
than sOVA+pIC+GpC. Adsorbing CpG along with OVA on
SUVs preserved the high CD8 response observed with SUV(OVA)
alone, with both medians higher than that of s(OVA+pIC+GpC).
Conversely, the addition of pIC resulted in a decrease of the CD8
response (p,0.05) (Figure 3A).
For one of the two CD4 epitopes assessed (Figure 3B), addition
of CpG to MLV(OVA) resulted in a significantly higher CD4
response (p = 0.002), equal to that induced by s(OVA+pIC+GpC).
The CD4 responses measured after vaccination with DRVs
containing OVA and TLR agonists showed relatively low but
comparable median values. Among the SUV liposomal formula-
tions tested, analogous to the observed CD8 response, the highest
proportion of CD4+IFNc+ cells were induced with the formulation
lacking the TLR agonists, the addition of which resulted in a non-
significant reduction of the CD4 response.
Antibody titres at the final time-point (14 weeks) showed a
similar trend to the T cell responses with respect to the addition of
Figure 2. Cellular and humoral responses following different liposome + OVA formulations. The DDA:TDB+OVA formulations indicated
along the X-axis were given to C57/BL6 mice as three homologous injections, two weeks apart. Splenocytes were isolated at the final timepoint (14
weeks) and responses to a CD8 OVA epitope (A) and two CD4 epitopes (B, C) were assessed by ex vivo IFNc ELISpot. D) Total IgG antibody responses
to whole OVA protein at the final time-point, as measured by an end-point titre ELISA. *p,0.05, ** p,0.01.
doi:10.1371/journal.pone.0034255.g002
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pIC and CpG to the liposome/OVA formulations (Figure 3D).
Adsorbing CpG to MLV(OVA) resulted in significantly higher
titres as compared to MLV+sOVA (p,0.009) and reached highest
median titre of all of the tested formulations. This formulation also
induced a stronger humoral response than the non-liposomal
combination of the three components (p,0.05). In contrast to
CD8 responses, DRV(OVA) was significantly more potent in
inducing IgG titres compared to the pIC and CpG-containing
DRV formulations (p,0.05). SUV liposomes also produced high
IgG responses, although a slight decrease was detected when both
CpG and pIC were added to SUV(OVA). It should be noted that
several formulations, both with and without TLR agonists,
resulted in significantly higher titres than s(OVA+pIC+CpG).
Analysis of the relative proportions of IgG subclasses induced in
peripheral blood demonstrated that all of the formulations resulted
in IgG2a/IgG1 ratio of around 1, indicating no preferential Th1
or Th2 antibody response (data not shown).
Unlike DDA:TDB, neutral (DSPC/TDB) liposomes do not
interfere with the immunogenicity of viral vectored
vaccines
As mentioned previously, protein vaccines are poorly immuno-
genic. In contrast, potent immune responses, humoral, and in
particular cellular, can be induced if the antigen is delivered
encoded within a viral vector. To investigate whether liposomes as
adjuvants would interfere with immunogenicity of such vectors, we
tested cationic (DDA:TDB) and neutral (DSPC/TDB) SUVs and
Figure 3. Cellular and humoral responses to DDA:TDB liposomal formulations with OVA±TLR3 and TLR9 agonists. Following three
homologous injections of each DDA:TDB liposomal formulation, T cell and antibody responses were assessed at the terminal time-point (14 weeks).
Mouse splenocytes were isolated and T cell responses to an OVA CD8 epitope (A) and two CD4 epitopes (B and C) measured by IFNc ELISpot. D) Total
IgG titre in the serum at the terminal timepoint, assessed by end-point ELISA. *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0034255.g003
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MLVs in combination with two non-replicating viral vectors,
adenovirus (Ad) and Modified Vaccinia Ankara (MVA).
We assessed immune responses following a single injection of Ad
or two injections of MVA (prime-boost, 1 week apart), both
encoding TIPeGFP - a string of CD4 and CD8 T cell epitopes and
GFP protein as a model Ag for measuring antibody responses -
with or without liposomes (Figure 4). We found that cationic
liposomes, both SUVs and MLVs, completely abrogated cellular
and humoral immune responses induced by the adenoviral
construct Ad-TIPeGFP, and to a large degree the T cell responses
following MVA-TIPeGFP vaccination. This was anticipated, as
the surface of the Ad virus is strongly negatively charged and
cationic DDA:TDB liposomes would have occluded the CAR
receptor and prevented cell entry of the Ad virus. The majority of
the MVA particles are enveloped by the cell membrane, which is
also negatively charged, and would be similarly likely to be coated
by cationic liposomes that would interfere with cell entry.
We therefore tested neutral distearoyl-glycero-3-phosphocho-
lin/TDB (DSPC/TDB) SUV and MLV liposomes in combination
with the same viral vectors. Due to the lack of electric charge,
these liposomes form larger vesicles with more lipid bilayers in
comparison to cationic: neutral SUVs had a diameter of
135620.6 nm and MLVs 15606240 nm. The DSPC/TDB
liposomes had no significant effect on the cellular immunogenicity
induced by MVA in the spleen, although a decreasing trend was
observed with MLVs for both CD4 and CD8 epitopes when
compared to MVA-only vaccination (Figure 4A, 4B, 4C). In
contrast, with Ad vector-delivered antigen DSPC/TDB MLVs
resulted in a slightly higher CD4 and CD8 responses that reached
statistical significance for one of the CD8 epitopes tested
(Figure 4B).
No detectable antibody responses against the OVA antigen
were induced following two injections of the MVA vectored
vaccine, either with or without liposomes. Humoral responses to
the Ad-vectored vaccine were not significantly affected by the
DSPC/TDB liposomes, although a weak decreasing trend was
observed with the SUVs (Figure 4D).
Discussion
We show here that cationic DDA:TDB liposomes of same
chemical composition but different size and lamellarity differ in
their ability to induce humoral and cellular immunity when
combined with a protein antigen. Small unilamellar liposomes
(,600 nm in diameter when combined with protein Ag) were able
to induce significantly higher cellular and humoral adaptive
immune responses than multilamellar vesicles with a two-fold
larger diameter. The antibody titres measured with SUV(OVA)
were higher than those reported previously following the same
vaccination regime with several potent adjuvants, including
Freund’s, ISA 720 and aluminium-based adjuvants [33]. Anti-
gen-specific CD8 T cells in particular were shown to be strongly
induced by DDA:TDB SUVs, despite a small reduction in the
amount of OVA incorporated into these liposomes compared to
MLVs (85% vs 95% of total dose of the OVA protein). This was
an unexpected finding, considering that the size difference
between these two formulations is only 2-fold, and that the
multilamellar vesicles contain a higher proportion of the
immunostimulatory component TDB than the single lipid-bilayer
SUVs. Without the adsorbed Ag, SUVs and MLVs differ in
diameter by around 10-fold and it is possible that a difference in
the endocytic pathways involved in the internalisation of the two
types of liposomes is affecting Ag presentation and the ensuing
immune response [34]. A recent study explored the effect of the
size of cationic liposomes on the T- and B cell responses and also
observed preferential phagocytosis by macrophages and higher
splenic IFNc production with smaller (,500 nm) versus larger
(.2 mm) liposomes, although, interestingly, there was no enhance-
ment of humoral immunogenicity [35].
The primary aim of this work was to investigate the impact on
antigen-specific T cell and antibody responses of delivering the
antigen entrapped inside or adsorbed to the surface of the
liposomes. Similarly, in light of a previous report showing that
endocytosed and subsequently endosomally presented CpG ODN
can enhance cross-presentation to CD8 cells by Ag-presenting cells
[31], we sought to investigate the effect of delivering TLR agonists
CpG and poly I:C, either encapsulated within liposomes or
attached to the liposomal surface, on Ag-specific CTL responses in
mice.
With respect to Ag location, comparing MLV and DRV
liposome formulations, we found that slightly higher antibody
titres and CD4 T cell responses, can be achieved by delivering the
Ag encapsulated within the liposomes, as compared to a surface-
adsorbed Ag. Although the trend observed in our system was not
statistically significant, it lends support to an earlier study that
showed an enhancement in Ab production when BSA protein was
delivered inside phosphatydylcholine/cholesterol liposomal vesi-
cles [20] and suggests that Ag entrapment could lead to better B
cell recognition through augmenting CD4 T cell help. A recent
study comparing immune responses to the entrapped versus
adsorbed tuberculosis antigen Ag85-ESAT-6 in Balb/c mice,
however, found that both DDA:TDB MLV and DRV formula-
tions appeared to result in similar IgG titres [36].
Cationic DDA:TDB liposomes have been considered unable to
elicit potent CD8 responses without the addition of a TLR agonist
[15] and our results support previous reports that TLR3 and
TLR9 agonists can help generate CD4 and CD8 T cell responses
to a liposome delivered Ag in vivo [22]. However, the added TLR
agonists were only able to enhance immune responses when
combined, either entrapped or surface adsorbed, with larger
liposomes (MLVs or DRVs). In contrast, the smaller SUV
liposomes induced strong CD8 IFNc production in the absence
of TLR agonists, the addition of which even led to a decrease
(non-significant) of the assayed immune responses. The cause of
this decrease in immunogenicity, which was mainly evident in the
T cell responses, is not clear, although we noted two side-effects
arising from adding TLR agonists to SUV liposomes. One was an
increase in the liposomal diameter to nearly twice that of SUVs
containing OVA only, and the other a reduction in the amount of
liposome-entrapped OVA protein with the inclusion of CpG and
poly I:C by around a third. Either or both of these could have led
to the observed reduction in the CD4 and CD8 responses in this
group. Another recent study looking at encapsulation of OVA and
TLR agonists PAM3CSK and CpG within cationic liposomes also
observed a 25% reduction in the entrapped OVA when the TLR
agonists were added, as well as no increase in the total IgG titres in
the animals receiving this formulation, thus supporting our
findings [23].
A previous study by Tanaka et al. [37] investigated the role of
saturated and non-saturated fatty acid liposomes in Ag targeting to
the class I or class II processing pathways in vitro. They found that
liposomes composed of stearoyl acid (saturated fatty acid with 18
C chain) were more effective in targeting the antigen to the MHC
class II processing pathway, whilst oleoyl (18 C fatty acid with a
single double bond) liposomes were successfully targeting OVA to
both class I and II processing. Our study employed liposomes
composed of DDA, a saturated fatty acid containing 18 C residues
and hence equivalent to stearoyl acid. Our observation of a
Cationic Liposomes as Vaccine Adjuvants
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Figure 4. Cellular and humoral responses to liposome-adjuvanted viral vectored vaccines. T cell and antibody responses were assessed
in Balb/c mice at peak time-points for Adenovirus (Ad) and Modified Vaccinia Ankara (MVA) viral vectored vaccines expressing TIPeGFP, i.e. two weeks
after a single injection of Ad and one week after two injections of MVA, combined with cationic DDA:TDB or neutral DSPC/TDB liposomes. Spleen T
cell responses to two CD8 (A, B) and one CD4 epitope (C), contained within the insert of the viral constructs, were measured using IFNc ELISpot. D)
Total IgG titre in the serum of mice immunised with the Ad+liposome formulations at the peak time-point. **p,0.01.
doi:10.1371/journal.pone.0034255.g004
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significant enhancement of both CD4 and CD8 Ag-specific
responses with SUV liposomes as compared to MLVs suggests
that the liposomal size and lamellarity, rather than the number of
double bonds in the fatty acid chain, could be a more significant
determinant in targeting the antigen for MHC class I or II
presentation. Similarly, using small unilamellar liposomes appears
to circumvent the need for a pH-sensitive liposome delivery
system, which has been shown to induce CTL response against the
protein antigen [38].
We also assessed the ability of liposomes to enhance
immunogenicity of viral vectored vaccines, which are intrinsically
immunogenic and difficult to adjuvant further. As predicted,
cationic liposomes completely abrogated the immunogenicity of
the Adenovirus vectored vaccine, probably due to the opposing
surface charges between DDA:TDB and the negatively charged
Ad virus, which would lead to liposome coating of the virus and
prevent cell entry. Similar effect was observed with the MVA
vectored vaccine (where most particles would be enveloped by a
cell membrane and hence also negatively charged) and cationic
liposomes. Non-charged DSPC/TDB liposomes did not have the
neutralising effect of the DDA:TDB vesicles, and were able to
enhance both CD4 and CD8 T cell responses induced by the Ad
vector. MLVs in particular were more potent than SUVs in
adjuvanting the Ad vector. It has been shown that Adenovirus can
enter the cell through macropinocytosis [39,40] and the liposomes
administered with the Ad vector are likely to have been taken up
by the cells through the same mechanism [41]. This could explain
the observed increase in CD8 T cell responses to the Ad vector
delivered antigen, as macropinocytosis has been implicated in
cross-presentation by DCs in vivo [42,43].
In summary, our study demonstrates that addition of TLR
agonists CpG and poly I:C to cationic DDA:TDB liposomes
formulated with protein Ag can enhance the immunogenicity of
MLV but not SUV or DRV liposomes, as measured by both pro-
inflammatory cellular (CD4 and CD8) and IgG antibody
responses. This finding was partially due to the potent adjuvanting
effect of the small unilamellar DDA:TDB vesicles alone, which
was equivalent to, or higher than, that measured with the protein
Ag with TLR agonists in solution. The observations presented
here could be of use when choosing liposomes as protein antigen
delivery vehicles and adjuvants, as they could circumvent the need
for inclusion of TLR agonists, and the potential clinical safety-
related issues associated with TLR agonists, in liposome-
adjuvanted vaccines.
Materials and Methods
Preparation of liposomes
MLVs were prepared using the previously described lipid-film
hydration method (Bangham et al 1965). Briefly, weighed amounts
of DDA (or DSPC) and TDB were dissolved in chloroform/
methanol (9:1 by volume) and the organic solvent was removed by
rotary evaporation, followed by flushing with N2 to form a thin
lipid film on the bottom of a round-bottomed flask. The lipid film
was hydrated in 10 mM Tris-buffer at pH 7.4 by heating for
20 min at 60uC.
To generate SUVs, the MLV were disrupted using sonic energy
to fracture large liposomes into smaller structures (,100 nm). The
tip of a sonicator probe (Soniprep 150) was placed onto the
liposome surface of the MLV mixture, transforming the milky
MLV suspension into a clear SUV suspension.
For the preparation of DDA:TDB DRVs, SUVs were stirred in
the presence or absence of OVA, CpG and poly I:C, frozen at
270uC, and freeze dried overnight (240uC, vacuum to 40 mbar).
Controlled rehydration of the dried powder, leading to the
formation of antigen-containing DRVs, was achieved by addition
of distilled water in aliquots equalling 10% of the final volume
(which was standardised at 1 mL), with vortexing and 30 min
incubation at room temperature following addition of each aliquot
[44]. DRV preparations were then centrifuged twice at
45,000 rpm for 20 min to remove non-entrapped components
and resuspended in PBS to the appropriate volume. To determine
antigen adsorption/entrapment, OVA (grade VII, Sigma, UK)
was radio-labelled with I125 and liposome formulations were
prepared as described above.
Determination of vesicle size and zeta potential
Samples were diluted in 10 mM Tris-buffer at pH 7.4 to
achieve optimal vesicle concentration. Vesicle size and zeta-
potential were determined using photon correlation spectroscopy
(PCS), at 25uC, using ZetaPlus (Brookhaven Instrument Corpo-
ration, USA).
Mice and immunizations
Ethics Statement: All procedures were performed under the UK
Home Office personal project licence PPL 30/2414, and approved
by the University of Oxford Animal Care and Ethical Review
Committee, in accordance with the terms of the UK Animals
(Scientific Procedures) Act Project Licence.
Female BALB/c (H-2d) or C57BL/6 (H-2b) mice 6–8 weeks of
age (Harlan Laboratories, Oxfordshire, UK) were anesthetized
with Isofluorane (Isoflo, Abbot Animal Health, UK) prior to the
immunizations. All immunisations were administered intramuscu-
larly (i.m.) into the gastrocnemius muscle by delivering 25 ml per
limb (50 ml per mouse). Three injections of each OVA/liposome
formulation were given at two weeks intervals. Doses of each
component per injection per mouse were as follows: OVA 20 mg,
DDA:DSPC 250 mg, TDB 50 mg, CpG 20 mg and poly I:C 50 mg.
AdHu5 and MVA viral vectors containing an insert consisting of
TIP (described in [45]) and Green Fluorescent Protein (GFP), named
TIPeGFP, were administered at 106 pfu/mouse (MVA TIPeGFP)
and 108 iu/mouse (Ad TIPeGFP). In all animals the immune
responses were assayed two weeks after each immunization.
ELISA
Total IgG ELISA was carried out as described previously [46].
Briefly, whole OVA or GFP protein was adsorbed to 96-well
Nunc-Immuno Maxisorp plates (Fisher Scientific, Wohlen,
Germany) at 2 mg/mL final concentration. Mouse sera were
typically diluted to 1:100, added to wells in duplicate and further
serially diluted. Bound antibodies were detected using alkaline
phosphatase-conjugated goat anti-mouse total IgG (Sigma)
followed by incubation with extravidin alkaline phosphatase
conjugate (Sigma, UK). Plates were developed by adding p-
nitrophenylphosphate substrate (Sigma, UK) and optical density
read at 405 nm (OD405) once the colour started developing. A
positive serum sample of known OD was added as control for each
assay. Endpoint titers were taken as the x-axis intercept of the
dilution curve at absorbance value 3 standard deviations greater
than the OD405 for naı¨ve mouse serum (typical cut-off OD405 for
positive sera = 0.15).
Ex-vivo IFNc ELISPOT
The number of IFNc secreting antigen-specific T cells in fresh
splenocyte preparations was determined using the standard IFNc
ELISpot assay. In brief, 96-well MAIP ELISPOT plates (Milli-
pore, UK) were coated with anti-mouse-IFNc mAb (Mabtech,
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UK) at 5 mg/mL in carbonate-bicarbonate buffer. Plates were
blocked with DMEM (Sigma Aldrich, UK) containing 10% FBS
(Biosera Ltd, UK), 2 mM L-glutamine, 100 U/mL penicillin and
100 mg/mL streptomycin sulphate (all from Invitrogen, UK) for
1 h at 37uC. Following the removal of erythrocytes using ACK
Lysis buffer, splenocytes from immunised mice were added in
duplicate to the coated wells at 500,000, 250,000 and 125,000 cells
per well. Peptides corresponding to known OVA CD8 and CD4 T
cell epitopes SIINFEKL (OVA257–264), TEWTSSNVMEER-
KIKV (OVA265–280) and ISQAVHAAHAEINEAGR (OVA323–
339), or epitopes contained within the viral vectored insert
TIPeGFP: the H2-Kd-restricted SYIPSAEKI (from P. berghei),
HYLSTQSAL (from GFP) and TFLTSELPGWLQANRHVKPT
(tuberculosis antigen 85A P15 epitope) were added to the test wells
at the final concentration of 1–5 mg/mL. Following overnight
incubation, cells were discarded and plates incubated with
biotinylated anti-mouse-IFNc mAb (Mabtech, UK), followed by
a streptavidin alkaline phosphatase polymer (Mabtech, UK). Spots
were developed by addition of colour development reagent
(Alkaline Peroxidase conjugate substrate kit, BioRad, UK) and
counted using ELISPOT software (Autoimmun Diagnostika,
Germany). Background responses in non-peptide stimulated wells
were subtracted from the test wells. Results are expressed as spot
forming cells (SFC) per million cells.
Statistical analysis
All statistical analyses were done using the statistical software
integral to the GraphPad Prism software (GraphPad Software Inc.,
USA). One-way ANOVA analysis was used for the determination
of statistical significance, unless otherwise specified.
Supporting Information
Figure S1 OVA retention profile for the liposomal OVA/
TLR formulations. The proportion of OVA retained in (A)
MLV, (B) DRV and (C) SUV liposomal formulations, either stored
in Tris buffer or in Tris supplemented with 50% FCS at 37uC
(simulated in vivo conditions). Using I125-labelled OVA, aliquots of
each formulation were incubated in a shaking water bath at 37uC
for 96 h. At the indicated time intervals, samples were centrifuged
twice and OVA release was calculated as a percentage of the
recovered radioactivity. Results represent Mean 6 SD of triplicate
experiments.
(TIF)
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